Takeda

BioMed Realty Announces 2023 ESG Achievements

Retrieved on: 
Wednesday, October 25, 2023
Environmental, Social and Governance (ESG), Commercial Building & Real Estate, Construction & Property, Sustainability, Other Health, Technology, Consulting, Professional Services, Environment, Environmental Health, Other Technology, Biotechnology, Science, Other Science, Health, Other Construction & Property, Benchmark, Takeda Pharmaceutical Company, San Francisco Bay Area, Child, Real estate, ESG, LEED, BioMed Central, Gold, Electricity, Biophysical environment, Research, Social, LED, Organic, Partnership, HVAC, Investment, Hunger, Social Security Government Pension Offset, Property management, Takeda

BioMed Realty (“Company”), a leading provider of real estate solutions to the life science and technology industries, today provided highlights of its continued 2023 Environmental, Social and Governance (ESG) achievements.

Key Points: 
  • BioMed Realty (“Company”), a leading provider of real estate solutions to the life science and technology industries, today provided highlights of its continued 2023 Environmental, Social and Governance (ESG) achievements.
  • BioMed Realty is a portfolio company within Blackstone’s Core+ Life Sciences Real Estate strategy, which achieved a 5 Star Rating in the 2023 GRESB Real Estate Assessment .
  • The GRESB Real Estate Assessment is the leading ESG benchmark for real estate and infrastructure investments across the world.
  • “Investors and tenants are increasingly demonstrating a preference for sustainable buildings, and BioMed Realty’s ESG initiatives will continue to set our portfolio and Company apart.

GC Cell Joins U.S Cancer Moonshot Project

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, Cancer Moonshot, Dime, AstraZeneca, H. Lee Moffitt Cancer Center & Research Institute, Multi, Life, Mortality, Yale Physician Associate Program, Monroe Dunaway Anderson, Dana–Farber Cancer Institute, CDMO, Research, CGT, Korean Ministry of Culture, Genomics, Liver cancer, Intel, NK, Partnership, Natural killer cell, Cancer, AI, Johnson & Johnson, Patient, Mayo Clinic, Medical imaging, Pharmaceutical industry, Vaccine, Food, Takeda, Amazon, Oracle

YONGIN, South Korea, Oct. 24, 2023 /PRNewswire/ -- GC Cell, led by CEO James Park, has announced its participation in CancerX, part of the U.S. Cancer Moonshot project. The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years. In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.

Key Points: 
  • YONGIN, South Korea, Oct. 24, 2023 /PRNewswire/ -- GC Cell, led by CEO James Park, has announced its participation in CancerX, part of the U.S. Cancer Moonshot project.
  • The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years.
  • In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.
  • Through Cancer Moonshot participation, GC Cell aims to highlight the importance and potential of cell therapy in cancer treatment.

Dr. Benjamin Wolozin to Present "Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology" at CTAD 2023

Retrieved on: 
Tuesday, October 24, 2023
FDA, MIT, Cognition, Vaccine, Neuron, Hope, Takeda, Neurology, LabCentral, Pathology, Boston Park Plaza, Entrepreneurship, Research, Protein, Manhattan Center, Brain damage, Anatomy, Pfizer, ALS, Boston University School of Public Health, Killing Floor 2, Tau, AbbVie, Foundation for the National Institutes of Health, Patient, Kendall Square, Neuroscience, Alzheimer's Association, Memory, Pharmaceutical industry, Medical imaging, Alzheimer's disease

CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, today announced that the company's Co-Founder and Chief Scientific Officer, Dr. Benjamin Wolozin MD, Ph.D., will be presenting new preclinical research at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference. CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.

Key Points: 
  • CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.
  • CTAD 23 is sold out, but attendees can still register for virtual attendance.
  • Our therapeutic removes abnormal tau protein, which is the key protein contributing to loss of memory and cognition in Alzheimer's disease.
  • If successful in clinical trials, Aquinnah's treatment offers the hope of reducing the brain damage and correspondingly restoring brain function for patients suffering from Alzheimer's disease."

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Retrieved on: 
Wednesday, October 18, 2023
Dravet syndrome, Lennox–Gastaut syndrome, Epilepsy, Growth, Seizure, LGS, Finance, SAN, Pharmaceutical industry, Takeda, Ligand

In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.

Key Points: 
  • In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.
  • “We are pleased to partner with Ligand which recognizes the potential value of our royalty and milestone payments associated with soticlestat,” said Jeffrey Rona, Chief Business and Financial Officer of Ovid.
  • With this additional, non-dilutive capital infusion from Ligand, Ovid anticipates that its cash runway is expected to last into 2026 and will enable the expansion of its clinical programs.
  • Ovid has no ongoing obligations or costs associated with the development of soticlestat.

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Retrieved on: 
Wednesday, October 18, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Survival, Brentuximab vedotin, Christie, TAK, Progression-free survival, CHMP, European Commission, IRF, Committee, Bleomycin, Vinblastine, European Directive on Traditional Herbal Medicinal Products, AVD, Doxorubicin, PFS, EC, University of Manchester, Civil service commission, Hodgkin lymphoma, ADC, CD30, ABVD, Risk, Dacarbazine, University, The Christie NHS Foundation Trust, Committee for Medicinal Products for Human Use, Hatim al-Awni, Overalls, Safety, ADCETRIS, Patient, OS, Lymphoma, Medical device, Medical imaging, Pharmaceutical industry, Takeda, Fellow of the Academy of Medical Sciences

Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma.
  • ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma, and has been previously approved as a therapy for adult patients in Europe in six distinct indications, including those with previously untreated CD30+ Stage IV Hodgkin lymphoma.
  • The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on September 14, 2023.
  • “We are thrilled with the decision of the European Commission to approve ADCETRIS in combination with chemotherapy as a treatment for adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma, particularly as up to one third of patients with Stage III & IV disease are at risk of experiencing treatment failure with current regimens,” said Awny Farajallah, M.D., head of global medical affairs oncology, Takeda.

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas

Retrieved on: 
Wednesday, October 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, GI, Inflammation, TAK, CPF, Observational study, Asset, INSPIRE, Safety, European, Patient, Pharmaceutical industry, Medical device, Takeda, Darvadstrocel

Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data.

Key Points: 
  • Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data.
  • The safety profile for darvadstrocel was consistent with prior studies and there were no new safety signals identified.
  • “While we are disappointed with this outcome, we recognize that medical research for difficult-to-treat conditions such as complex CPF remains challenging," said Chinwe Ukomadu, head of the GI & Inflammation Therapeutic Area Unit at Takeda.
  • Any revisions to the consolidated forecast for the fiscal year ending March 31, 2024 (FY2023) will be announced during Takeda’s second quarter earnings call, scheduled for October 26, 2023.

Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

Retrieved on: 
Wednesday, October 18, 2023
Biotechnology, Pharmaceutical, Health, Shire (pharmaceutical company), TAK, TAC, Acquisition, Bank statement, Wisconsin Tax Appeals Commission, Revenue Commissioners, EUR, USD, AbbVie, IST, Pharmaceutical industry, Takeda

Takeda ( TSE:4502/NYSE:TAK ) today announced that, on October 17, 2023 (IST), it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”), for EUR 130 million, resulting in a tax expense reduction of approximately JPY 63 billion for Takeda.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that, on October 17, 2023 (IST), it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”), for EUR 130 million, resulting in a tax expense reduction of approximately JPY 63 billion for Takeda.
  • On November 28, 2018, Shire received a tax assessment from the Irish Revenue for EUR 398 million in relation to the USD 1,635 million break fee Shire received in connection with the terminated offer by AbbVie to acquire Shire in 2014.
  • Takeda appealed this assessment, and in late 2020 a hearing took place before the Irish Tax Appeals Commission (“TAC”).
  • On July 30, 2021, Takeda received a ruling on the matter, with the TAC ruling in favor of Irish Revenue.

Government of Serbia and Ginkgo Bioworks Announce Bioeconomy Collaboration in BIO4 Campus

Retrieved on: 
Thursday, October 19, 2023
MSD, Government of Serbia, Government, BGI, AstraZeneca, Biodiversity, Ginkgo Bioworks, NYSE, Innovation, Health, Food, Biotechnology, Motivation, Ministry of Science, Technological Development and Innovation (Serbia), Doctor of Philosophy, Ginkgo, Entrepreneurship, Memorandum of understanding, Research, Fourth Industrial Revolution, Swarrnim Startup & Innovation University, Biology, Ecosystem, Partnership, Roche, Synthetic biology, Agriculture, Map, Startup accelerator, DNA, Forestry, Pharmaceutical industry, Science, Takeda, Merck, Pfizer

The BIO4 campus initiative already gathers more than 1,000 PhD scientists from 17 scientific institutions, and the campus itself will open in 2026.

Key Points: 
  • The BIO4 campus initiative already gathers more than 1,000 PhD scientists from 17 scientific institutions, and the campus itself will open in 2026.
  • Within the envisioned collaboration, companies on the BIO4 campus will have the opportunity to take advantage of incentives to access Ginkgo's platform.
  • Further, under the MoU, Ginkgo and the Government of Serbia will also explore partnerships to develop and implement new biomonitoring capabilities in Serbia.
  • The Centre is part of the C4IR network, and co-founded by the World Economic Forum and the Government of Serbia.

Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer

Retrieved on: 
Wednesday, October 18, 2023
Science, University of Texas Southwestern Medical Center, AstraZeneca, IND, Molecular biology, Biomarker, Human, Genetics, Takeda, Investigational New Drug, University, CTA, Merck, PALO, Inflammation, Research, R, Drug development, McLean, DSM-IV codes, Novomer, Medicine, Russell Travers, Osteoarthritis, Patient, Doctor of Philosophy, Pharmaceutical industry, Lachy, Genentech

PALO ALTO, Calif., Oct. 18, 2023 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Ian Lachlan (Lachy) McLean, M.D., Ph.D. as its chief medical officer. Dr. McLean brings extensive leadership experience in both early and late-stage clinical research and development (R&D) in the biopharmaceutical space, as well as complimentary clinical practice expertise as a rheumatologist to Genascence. He will lead Genascence's clinical development strategy.

Key Points: 
  • —Seasoned physician-scientist and R&D executive, with significant experience building and growing successful clinical development organizations—
    PALO ALTO, Calif., Oct. 18, 2023 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Ian Lachlan (Lachy) McLean, M.D., Ph.D. as its chief medical officer.
  • "On behalf of the entire Genascence organization and board of directors, I am thrilled to welcome Lachy as our chief medical officer," said Thomas Chalberg, Ph.D., founder and CEO of Genascence.
  • "Genascence is at the forefront of transforming how we treat prevalent and debilitating musculoskeletal diseases like osteoarthritis with gene therapy," said Dr. McLean.
  • Before joining Genascence, Dr. McLean was chief medical officer at Novome, a start-up biotech company developing engineered bacteria as a drug-delivery platform.

SERAMOUNT REVEALS THE 2023 100 BEST COMPANIES

Retrieved on: 
Tuesday, October 10, 2023
Fertilisation, Parent, Hospital, KPMG LLP, Organization, Caregiver, Grief, Johnson & Johnson, Travel, Goldman Sachs, Standard Chartered, Ernst & Young, Bank of America, Merck, Bank, KPMG, Accounting, Nursing, Takeda

Washington, DC, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Seramount, a strategic professional services and research firm, revealed its annual list of the 2023 100 Best Companies for working parents today.

Key Points: 
  • Washington, DC, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Seramount, a strategic professional services and research firm, revealed its annual list of the 2023 100 Best Companies for working parents today.
  • “Our 100 Best Companies are going the extra mile to create inclusive work environments for their parents and caregivers,” says Subha V. Barry, President of Seramount.
  • Key findings from the 2023 100 Best Companies:
    The 100 Best Companies offer an average of 11 weeks of fully paid parental leave for full-time employees, the same as 2022.
  • More 100 Best Companies are subsidizing everyday childcare (39 percent in 2023 vs. 36 percent in 2022) as well as sick-child care (72 percent in 2023 vs. 68 percent in 2022).